| Aug 10 |
Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript
|
| Aug 8 |
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
|
| Aug 8 |
Akebia GAAP EPS of -$0.04, revenue of $43.67M
|
| Aug 8 |
Akebia Therapeutics: Q2 Earnings Snapshot
|
| Aug 8 |
Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
|
| Aug 2 |
Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights
|
| Jul 29 |
Akebia Therapeutics to Present at Upcoming Investor Conferences
|
| Jul 11 |
Akebia Regains Full Rights to Sell Vafseo Tablets in US After Ending Licensing Deal With CSL Vifor
|
| Jul 11 |
Akebia regains full rights to kidney disease therapy from CSL
|
| Jul 11 |
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets
|
